Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 6.32
ALNY's Cash-to-Debt is ranked lower than
60% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. ALNY: 6.32 )
Ranked among companies with meaningful Cash-to-Debt only.
ALNY' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.29  Med: No Debt Max: No Debt
Current: 6.32
Equity-to-Asset 0.78
ALNY's Equity-to-Asset is ranked higher than
67% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ALNY: 0.78 )
Ranked among companies with meaningful Equity-to-Asset only.
ALNY' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.99  Med: 0.65 Max: 0.92
Current: 0.78
-0.99
0.92
Debt-to-Equity 0.14
ALNY's Debt-to-Equity is ranked higher than
68% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. ALNY: 0.14 )
Ranked among companies with meaningful Debt-to-Equity only.
ALNY' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.07  Med: 0.1 Max: 0.33
Current: 0.14
-0.07
0.33
Debt-to-EBITDA -0.33
ALNY's Debt-to-EBITDA is ranked lower than
99.99% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. ALNY: -0.33 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ALNY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.37  Med: -0.23 Max: -0.09
Current: -0.33
-0.37
-0.09
Interest Coverage N/A
ALNY's Interest Coverage is ranked lower than
55% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALNY: N/A )
Ranked among companies with meaningful Interest Coverage only.
ALNY' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: N/A
N/A
No Debt
Piotroski F-Score: 3
Altman Z-Score: 22.18
Beneish M-Score: -2.59
WACC vs ROIC
22.49%
-121.50%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -674.26
ALNY's Operating Margin % is ranked lower than
71% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. ALNY: -674.26 )
Ranked among companies with meaningful Operating Margin % only.
ALNY' s Operating Margin % Range Over the Past 10 Years
Min: -900.33  Med: -188.54 Max: -28.95
Current: -674.26
-900.33
-28.95
Net Margin % -664.70
ALNY's Net Margin % is ranked lower than
71% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. ALNY: -664.70 )
Ranked among companies with meaningful Net Margin % only.
ALNY' s Net Margin % Range Over the Past 10 Years
Min: -869.63  Med: -163.4 Max: -27.3
Current: -664.7
-869.63
-27.3
ROE % -46.64
ALNY's ROE % is ranked lower than
53% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. ALNY: -46.64 )
Ranked among companies with meaningful ROE % only.
ALNY' s ROE % Range Over the Past 10 Years
Min: -84.12  Med: -39.64 Max: -13.08
Current: -46.64
-84.12
-13.08
ROA % -35.49
ALNY's ROA % is ranked higher than
50% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. ALNY: -35.49 )
Ranked among companies with meaningful ROA % only.
ALNY' s ROA % Range Over the Past 10 Years
Min: -48.05  Med: -23.41 Max: -5.01
Current: -35.49
-48.05
-5.01
ROC (Joel Greenblatt) % -372.68
ALNY's ROC (Joel Greenblatt) % is ranked lower than
51% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. ALNY: -372.68 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ALNY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2120.98  Med: -554.62 Max: -149.42
Current: -372.68
-2120.98
-149.42
3-Year Revenue Growth Rate -10.40
ALNY's 3-Year Revenue Growth Rate is ranked lower than
66% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ALNY: -10.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ALNY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -8.15 Max: 108
Current: -10.4
0
108
3-Year EBITDA Growth Rate 52.70
ALNY's 3-Year EBITDA Growth Rate is ranked higher than
87% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. ALNY: 52.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ALNY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -64.8  Med: 3.5 Max: 65.3
Current: 52.7
-64.8
65.3
3-Year EPS without NRI Growth Rate 48.90
ALNY's 3-Year EPS without NRI Growth Rate is ranked higher than
88% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. ALNY: 48.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ALNY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -66.7  Med: 6.6 Max: 52.8
Current: 48.9
-66.7
52.8
GuruFocus has detected 4 Warning Signs with Alnylam Pharmaceuticals Inc ALNY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ALNY's 30-Y Financials

Financials (Next Earnings Date: 2018-02-08)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

ALNY Guru Trades in Q4 2016

Dodge & Cox 9,204,950 sh (+74.47%)
Vanguard Health Care Fund 8,549,357 sh (+0.44%)
John Griffin 1,320,000 sh (unchged)
John Paulson 19,300 sh (unchged)
» More
Q1 2017

ALNY Guru Trades in Q1 2017

Jim Simons 51,100 sh (New)
Pioneer Investments 87,256 sh (New)
John Griffin 1,590,000 sh (+20.45%)
Dodge & Cox 9,399,245 sh (+2.11%)
Vanguard Health Care Fund 8,549,357 sh (unchged)
John Paulson Sold Out
» More
Q2 2017

ALNY Guru Trades in Q2 2017

Joel Greenblatt 9,684 sh (New)
George Soros 7,000 sh (New)
Steven Cohen 50,000 sh (New)
Pioneer Investments 147,194 sh (+68.69%)
Jim Simons Sold Out
Dodge & Cox 9,185,820 sh (-2.27%)
Vanguard Health Care Fund 8,047,957 sh (-5.86%)
John Griffin 1,376,700 sh (-13.42%)
» More
Q3 2017

ALNY Guru Trades in Q3 2017

Steven Cohen 85,000 sh (+70.00%)
John Griffin 1,531,899 sh (+11.27%)
Steven Cohen 150,000 sh (unchged)
Steven Cohen 100,000 sh (unchged)
George Soros Sold Out
Dodge & Cox 9,141,495 sh (-0.48%)
Vanguard Health Care Fund 7,945,504 sh (-1.27%)
Pioneer Investments 95,572 sh (-35.07%)
Joel Greenblatt 2,499 sh (-74.19%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ALNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Dodge & Cox 2017-09-30 Reduce -0.48%$72.53 - $118.27 $ 132.3355%9,141,495
Vanguard Health Care Fund 2017-09-30 Reduce -1.27%0.02%$72.53 - $118.27 $ 132.3355%7,945,504
Joel Greenblatt 2017-09-30 Reduce -74.19%0.01%$72.53 - $118.27 $ 132.3355%2,499
George Soros 2017-09-30 Sold Out 0.01%$72.53 - $118.27 $ 132.3355%0
Dodge & Cox 2017-06-30 Reduce -2.27%0.01%$47.75 - $85.21 $ 132.33108%9,185,820
Vanguard Health Care Fund 2017-06-30 Reduce -5.86%0.06%$47.75 - $85.21 $ 132.33109%8,047,957
Joel Greenblatt 2017-06-30 New Buy0.01%$47.75 - $85.21 $ 132.33108%9,684
George Soros 2017-06-30 New Buy0.01%$47.75 - $85.21 $ 132.33108%7,000
Dodge & Cox 2017-03-31 Add 2.11%0.01%$36.88 - $59.71 $ 132.33186%9,399,245
John Paulson 2017-03-31 Sold Out 0.01%$36.88 - $59.71 $ 132.33186%0
Dodge & Cox 2016-12-31 Add 74.47%0.13%$31.41 - $70.3 $ 132.33216%9,204,950
Vanguard Health Care Fund 2016-12-31 Add 0.44%$31.41 - $70.3 $ 132.33216%8,549,357
Dodge & Cox 2016-11-30 Add 71.95%0.16%Premium Member Access $43.87 $ 132.33202%9,072,450
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:KITE, OCSE:GEN, NAS:SGEN, XBRU:UCB, HKSE:01177, NAS:JAZZ, NAS:EXEL, NAS:ALKS, NAS:BMRN, NAS:IONS, SZSE:002252, HKSE:02269, NAS:BLUE, NAS:TSRO, NAS:BIVV, OCSE:NZYM B, NAS:JUNO, NAS:NBIX, NAS:UTHR, XAMS:GLPG » details
Traded in other countries:DUL.Germany,
Headquarter Location:USA
Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.

Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. Alnylam has partnered several pipeline candidates, including amyloidosis drug patisiran, hemophilia drug fitusiran, and cholesterol drug inclisiran. Up-front fees from research partnerships with firms such as Sanofi, Takeda, Roche, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see milestones and royalties from drugs commercialized under these agreements.

Top Ranked Articles about Alnylam Pharmaceuticals Inc

A Look at Alnylam Pharmaceuticals' Rolling NDA What the rolling NDA submission process looks like for patisiran
At the end of last week, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) announced it had initiated a rolling submission for a new drug application (NDA) rooted in an asset called patisiran. This is a drug that analysts expect could top out at more than $1 billion in annual sales for Alnylam if it is successful in garnering a regulatory greenlight from the U.S. Food and Drug Administration (FDA) and, as such, it is one that markets are keeping an eye on as strongly indicative of wider investor sentiment surrounding the company and its long-term prospects right now. Read more...
Arbutus’ LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran
Arbutus’ LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA)
Analysts Act on Health Care Stocks Leerink upgrades AbbVie to Outperform
Analysts have taken action on some health care stocks. Read more...
Arbutus’ LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alnylam Pharmaceuticals, Inc. (ALNY)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
High Return Covered Call Trades for Alnylam Pharmaceuticals, Lumber Liquidators, Nutrisystem, 500.Com, and Wix.com!

Ratios

vs
industry
vs
history
PB Ratio 11.56
ALNY's PB Ratio is ranked lower than
81% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. ALNY: 11.56 )
Ranked among companies with meaningful PB Ratio only.
ALNY' s PB Ratio Range Over the Past 10 Years
Min: 2.07  Med: 4.9 Max: 21.37
Current: 11.56
2.07
21.37
PS Ratio 167.50
ALNY's PS Ratio is ranked lower than
89% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. ALNY: 167.50 )
Ranked among companies with meaningful PS Ratio only.
ALNY' s PS Ratio Range Over the Past 10 Years
Min: 3.1  Med: 22.07 Max: 222.78
Current: 167.5
3.1
222.78
EV-to-EBIT -24.51
ALNY's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. ALNY: -24.51 )
Ranked among companies with meaningful EV-to-EBIT only.
ALNY' s EV-to-EBIT Range Over the Past 10 Years
Min: -61.7  Med: -11.3 Max: -1.3
Current: -24.51
-61.7
-1.3
EV-to-EBITDA -25.20
ALNY's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. ALNY: -25.20 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALNY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -95.7  Med: -12.2 Max: -1.4
Current: -25.2
-95.7
-1.4
EV-to-Revenue 165.22
ALNY's EV-to-Revenue is ranked lower than
84% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. ALNY: 165.22 )
Ranked among companies with meaningful EV-to-Revenue only.
ALNY' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.7  Med: 17.4 Max: 200.5
Current: 165.22
0.7
200.5
Current Ratio 9.83
ALNY's Current Ratio is ranked higher than
76% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ALNY: 9.83 )
Ranked among companies with meaningful Current Ratio only.
ALNY' s Current Ratio Range Over the Past 10 Years
Min: 1.88  Med: 5.16 Max: 18.24
Current: 9.83
1.88
18.24
Quick Ratio 9.83
ALNY's Quick Ratio is ranked higher than
77% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. ALNY: 9.83 )
Ranked among companies with meaningful Quick Ratio only.
ALNY' s Quick Ratio Range Over the Past 10 Years
Min: 1.88  Med: 5.16 Max: 18.24
Current: 9.83
1.88
18.24
Days Sales Outstanding 76.97
ALNY's Days Sales Outstanding is ranked lower than
64% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. ALNY: 76.97 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALNY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.57  Med: 34.48 Max: 288.31
Current: 76.97
0.57
288.31

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.50
ALNY's 3-Year Average Share Buyback Ratio is ranked higher than
58% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. ALNY: -10.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALNY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -331.8  Med: -15.2 Max: -1
Current: -10.5
-331.8
-1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 18.85
ALNY's Price-to-Net-Cash is ranked lower than
76% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. ALNY: 18.85 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ALNY' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.7  Med: 9.83 Max: 92.77
Current: 18.85
3.7
92.77
Price-to-Net-Current-Asset-Value 17.62
ALNY's Price-to-Net-Current-Asset-Value is ranked lower than
77% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. ALNY: 17.62 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ALNY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.54  Med: 9.24 Max: 82.06
Current: 17.62
3.54
82.06
Price-to-Tangible-Book 11.55
ALNY's Price-to-Tangible-Book is ranked lower than
73% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. ALNY: 11.55 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ALNY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.2  Med: 4.99 Max: 15.16
Current: 11.55
2.2
15.16
Price-to-Median-PS-Value 7.59
ALNY's Price-to-Median-PS-Value is ranked lower than
96% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. ALNY: 7.59 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALNY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15  Med: 1.14 Max: 8.73
Current: 7.59
0.15
8.73
Earnings Yield (Greenblatt) % -4.08
ALNY's Earnings Yield (Greenblatt) % is ranked higher than
60% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. ALNY: -4.08 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALNY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -79.8  Med: -8.9 Max: -1.6
Current: -4.08
-79.8
-1.6

More Statistics

Revenue (TTM) (Mil) $69.44
EPS (TTM) $ -5.24
Beta3.38
Short Percentage of Float14.25%
52-Week Range $35.98 - 147.63
Shares Outstanding (Mil)92.73

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 76 116 206
EPS ($) -5.44 -5.13 -4.37
EPS without NRI ($) -5.44 -5.13 -4.37
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}